Skip to main content

Table 5 Anthropometric variables during the intervention period and post- ingestion periods

From: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

  

Intervention period

post- ingestion period

Parameter

Group

n

Week-0

Week-4

Week-8

Week-12

Week-16

Body weight (kg)

Placebo

14

70.3 ± 9.6

70.1 ± 9.2

70.6 ± 9.0

70.1 ± 8.8

70.5 ± 9.3

GH

15

70.0 ± 9.9

69.5 ± 9.7

69.9 ± 9.7

69.6 ± 9.4

70.0 ± 9.7

GH + Caf 25

15

69.2 ± 9.0

69.1 ± 9.0

68.8 ± 9.2

68.6 ± 9.5

68.7 ± 9.5

GH + Caf 50

15

70.5 ± 7.4

70.2 ± 7.5

70.1 ± 7.7

69.8 ± 7.7

69.8 ± 8.0

GH + Caf 75

15

70.2 ± 6.5

69.8 ± 6.6

69.3 ± 6.9

68.8 ± 7.0

68.9 ± 7.0

ΔBody weight (kg)

Placebo

14

 

−0.26 ± 1.1

0.24 ± 1.2

−0.19 ± 1.7

0.16 ± 1.7

GH

15

 

−0.44 ± 1.0

−0.09 ± 0.9

−0.39 ± 1.1

0.08 ± 1.4

GH + Caf 25

15

 

−0.11 ± 0.8

−0.39 ± 1.0

−0.57 ± 1.1

−0.48 ± 1.7

GH + Caf 50

15

 

−0.29 ± 1.1

−0.44 ± 1.3

−0.67 ± 1.4

−0.67 ± 1.8

GH + Caf 75

15

 

−0.36 ± 1.0

−0.88 ± 1.4#

−1.43 ± 2.0

−1.27 ± 2.2

BMI (kg/m2)

Placebo

14

26.1 ± 1.1

26.1 ± 1.2

26.3 ± 1.1

26.1 ± 1.3

26.2 ± 1.2

GH

15

26.2 ± 1.6

26.1 ± 1.6

26.2 ± 1.6

26.1 ± 1.6

26.3 ± 1.6

GH + Caf 25

15

26.3 ± 1.2

26.2 ± 1.3

26.1 ± 1.3

26.0 ± 1.4

26.1 ± 1.6

GH + Caf 50

15

26.7 ± 1.8

26.6 ± 1.8

26.5 ± 1.9

26.4 ± 1.9

26.4 ± 2.0

GH + Caf 75

15

26.5 ± 1.2

26.4 ± 1.3

26.2 ± 1.3

25.9 ± 1.3*

26.0 ± 1.3

ΔBMI (kg/m2)

Placebo

14

 

−0.07 ± 0.37

0.14 ± 0.39

−0.02 ± 0.58

0.08 ± 0.57

GH

15

 

−0.15 ± 0.36

−0.01 ± 0.38

−0.13 ± 0.42

0.03 ± 0.53

GH + Caf 25

15

 

−0.05 ± 0.31

−0.14 ± 0.40

−0.23 ± 0.40

−0.19 ± 0.65

GH + Caf 50

15

 

−0.13 ± 0.42

−0.19 ± 0.52

−0.28 ± 0.56

−0.27 ± 0.70

GH + Caf 75

15

 

−0.13 ± 0.41

−0.35 ± 0.55#

−0.56 ± 0.74#

−0.51 ± 0.84

Waist (cm)

Placebo

14

90.9 ± 5.7

90.7 ± 5.5

91.1 ± 5.1

91.3 ± 4.8

91.3 ± 5.3

GH

15

90.6 ± 3.0

90.6 ± 3.5

90.6 ± 3.4

90.6 ± 3.3

90.6 ± 3.8

GH + Caf 25

15

90.4 ± 5.3

89.9 ± 5.9

89.3 ± 6.0*

89.1 ± 6.2*

89.5 ± 6.4

GH + Caf 50

15

90.0 ± 4.7

89.6 ± 5.0

89.7 ± 5.2

89.1 ± 5.8

88.8 ± 6.5

GH + Caf 75

15

91.0 ± 4.4

91.0 ± 3.9

90.3 ± 4.0

89.9 ± 3.5

89.8 ± 3.1

ΔWaist (cm)

Placebo

14

 

−0.12 ± 0.9

0.19 ± 1.4

0.44 ± 2

0.42 ± 2.1

GH

15

 

0.01 ± 1.0

−0.01 ± 1.4

−0.02 ± 1.3

−0.03 ± 1.3

GH + Caf 25

15

 

−0.49 ± 1.1

−1.17 ± 1.4#

−1.31 ± 1.6#

−0.96 ± 2.2

GH + Caf 50

15

 

−0.31 ± 1.1

−0.28 ± 1.3

−0.82 ± 1.9

−1.12 ± 2.6

GH + Caf 75

15

 

0.05 ± 1.0

−0.66 ± 0.9

−1.11 ± 1.7

−1.21 ± 2.2

Hip (cm)

Placebo

14

96.5 ± 5.1

96.3 ± 5.3

96.5 ± 5.1

96.9 ± 5.5

97.1 ± 5.6

GH

15

96.8 ± 2.9

96.6 ± 2.8

96.9 ± 2.8

96.4 ± 3.1

96.6 ± 2.8

GH + Caf 25

15

95.9 ± 4.4

96.1 ± 4.0

96.1 ± 4.0

96.0 ± 4.5

96.0 ± 5.0

GH + Caf 50

15

97.1 ± 3.1

96.8 ± 3.2

97.0 ± 3.2

97.0 ± 3.5

97.0 ± 3.4

GH + Caf 75

15

96.4 ± 4.6

96.2 ± 4.6

96.0 ± 4.6

95.5 ± 4.5

95.6 ± 4.6

ΔHip (cm)

Placebo

14

 

−0.17 ± 0.7

0.01 ± 1.1

0.37 ± 1.6

0.64 ± 1.4

GH

15

 

−0.17 ± 0.8

0.05 ± 1.3

−0.41 ± 1.2

−0.23 ± 1.5

GH + Caf 25

15

 

0.23 ± 0.8

0.17 ± 1.0

0.13 ± 1.4

0.06 ± 2.0

GH + Caf 50

15

 

−0.26 ± 0.8

−0.11 ± 1.3

−0.08 ± 1.7

−0.13 ± 2.0

GH + Caf 75

15

 

−0.21 ± 1.0

−0.39 ± 1.2

−0.85 ± 1.8

−0.79 ± 2.0

  1. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg, BMI Body Mass Index
  2. Mean ± SD, *p < 0.05, vs. baseline (week-0), (paired t-test), #p < 0.05 vs. placebo (Dunnett’s test or Steel’s test)
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us